Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.51 |
| ▸ | DRD2 | P14416 | 9/20 | 0.51 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31386108 | 0.89 | CNR2 (0.50) | DRD4DRD2CNR2DRD3MOGAT2 | |
| SCHEMBL31386068 | 0.89 | CNR2 (0.50) | DRD4DRD2CNR2DRD3MOGAT2 | |
| SCHEMBL28765394 | 0.82 | CNR2 (0.54) | DRD4DRD2CNR2DRD3 | |
| SCHEMBL16992189 | 0.81 | PDE2A (0.42) | DRD3 | |
| SCHEMBL1437654 | 0.81 | DRD4 (0.58) | DRD4CNR2 | |
| SCHEMBL31385790 | 0.80 | CNR2 (0.51) | DRD4DRD2CNR2DRD3MOGAT2 | |
| SCHEMBL31386000 | 0.80 | CNR2 (0.51) | DRD4DRD2CNR2DRD3MOGAT2 | |
| SCHEMBL31386069 | 0.79 | DRD4 (0.47) | DRD4DRD2CNR2DRD3MOGAT2 | |
| SCHEMBL16462936 | 0.76 | CNR2 (0.67) | DRD4DRD2CNR2DRD3 | |
| SCHEMBL2080158 | 0.76 | DRD3 (0.55) | DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | DRD4 4519/4885DRD2 4540/4885CNR2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.